Gene Editing Market: Global Market Size, Growrh, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Global Gene Editing Market: By Technology (Zinc Finger Nuclease (ZFN), Clustered regularly interspaced short palindromic repeats (CRISPR), Transcription activator-like effector nuclease (TALEN), Others),  by Application (Cell Line Editing, Targeted gene mutation, Animal Genome Editing, Plant Genome Editing), Product Type (Consumables, Instruments and Software), End-user (Pharmaceutical companies, Biotechnology Companies, Academics, Clinical Research Organizations) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: , Tag:

Report

Description

Gene Editing Market size was valued at USD 4.98 billion in 2021 and is expected to reach USD 16.36 billion by 2028, at a CAGR of 18.5% during the forecast period 2022-2028. Gene editing or genome editing is the type of genetic editing where DNA is inserted, replaced, or deleted in the genome of an organism in order to treat a specific disease by using molecular scissors or engineered nuclease. These nucleases create site-specific double-stranded breaks in desired locations in the genome. The induced double-stranded breaks are repaired through nonhomologous end-joining or homologous recombination resulting in targeted mutations (edits). Biotechnology and pharmaceutical sectors dominate the gene-editing market due to their applications in drug discovery and therapeutics. Rise in the usage of CRISPR and ZFN, companies are investing in innovative research for the development of novel gene-editing techniques. Many players are adopting various strategies which include collaborations for R&D outsourcing, mergers, and acquisitions, strategic or manufacturing activities that are driving the growth of the gene-editing market. For instance, in 2014, Thermo Fisher acquired Life technologies, to create unbeatable leadership in life sciences, research, specialty diagnostics, and applied markets. In 2014, Sigma-Aldrich Corporation (U.S.) entered into an agreement with Broad Institute of MIT and Harvard (U.S.) to use CRISPR technology. High growth potential in emerging regions provides lucrative opportunities to industry players.

Gene Editing Market

MARKET SUMMARY
-
18.5%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 18.5%
  • Largest Market– North-America
  • Fastest Growing Market– Asia-Pacific

Gene Editing Market

  • The global gene editing market report gives a comprehensive outlook on aquaculture across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
  • The report on the global gene editing market gives historical, current, and future market sizes (US$ Bn) on the basis of product type, application, technology, end user, and region.
Key Players
  • Horizon Discovery Group plc,
  • Origene Technologies, Inc.
  • System Biosciences, Inc.
  • Sangamo Therapeutics, Inc.
Gene Editing Market

Drivers And Restraints

Rise in the prevalence rate of cancer & other genetic disorders, increasing preference in the personalized medicine, companies investments towards R&D, and growth of biotechnology and pharmaceutical industries, increase in private and public sector funding, rapid advancements in sequencing and gene editing technologies, applications in various drug discovery processes are some of the factors propelling the growth of the gene-editing market. However, the global gene editing market is hindered by stringent government regulations to approve gene mutation projects, ethical issues, unavailability of gene editing-based therapeutics in the market, and lack of awareness among people regarding the safety of genetic interventions.


North-America got significant share

Gene Editing Market

On the basis of geographical regions, the gene-editing market is categorized into five regions: Europe, North America, Latin America, Asia Pacific, and Middle East & Africa. The gene editing market is dominated by North America due to the strong growth trend in the pharmaceuticals and biotechnology industries. Emerging economies of the Asia Pacific and Latin America are expected to show significant growth in the gene-editing market due to an increase in the number of laboratories in these regions and the development of existing ones for automation of various instrumentation systems, the expansion of leading gene-editing companies, and increased R&D spending.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

developments

  • In July 2017Cellectiswas granted the European Patent for the invention of the genetically engineering T-cells by adopting RNA-guided endonucleases, such as CRISPR associated protein 9 (Cas9) or Centromere and Promoter Factor 1(Cpf1 )
  • In July 2017 Sangamo Therapeutics, Inc. received the U.S.FDA Fast Track designation for in vivo gene editing product candidates SB-318 and SB-913 to treat Mucopolysaccharidosis Type I (MPS I) and MPS II
  • In November 2016, OriGene Technologies entered strategic agreement with EdiGene (Beijing, China) for the development of gene-wide knockout cells from laboratory cell lines which are commonly used

Key

Features of the Report

Gene Editing Market Segmentation


Location

GEOGRAPHY


Report

Company Profile

  • Cellectis S.A. (France),
  • Applied Stemcell, Inc. (U.S.),
  • Genscript (U.S.),
  • Merck KGaA (Germany),
  • Horizon Discovery Group plc,(U.K.),
  • Origene Technologies, Inc. (U.S.),
  • System Biosciences, Inc. (U.S.),
  • Sangamo Therapeutics, Inc.(U.S.),
  • Thermo Fisher Scientific (U.S), and
  • Transposagen Biopharmaceuticals, Inc.(U.S.)

Description

Gene Editing Market size was valued at USD 4.98 billion in 2021 and is expected to reach USD 16.36 billion by 2028, at a CAGR of 18.5% during the forecast period 2022-2028. Gene editing or genome editing is the type of genetic editing where DNA is inserted, replaced, or deleted in the genome of an organism in order to treat a specific disease by using molecular scissors or engineered nuclease. These nucleases create site-specific double-stranded breaks in desired locations in the genome. The induced double-stranded breaks are repaired through nonhomologous end-joining or homologous recombination resulting in targeted mutations (edits). Biotechnology and pharmaceutical sectors dominate the gene-editing market due to their applications in drug discovery and therapeutics. Rise in the usage of CRISPR and ZFN, companies are investing in innovative research for the development of novel gene-editing techniques. Many players are adopting various strategies which include collaborations for R&D outsourcing, mergers, and acquisitions, strategic or manufacturing activities that are driving the growth of the gene-editing market. For instance, in 2014, Thermo Fisher acquired Life technologies, to create unbeatable leadership in life sciences, research, specialty diagnostics, and applied markets. In 2014, Sigma-Aldrich Corporation (U.S.) entered into an agreement with Broad Institute of MIT and Harvard (U.S.) to use CRISPR technology. High growth potential in emerging regions provides lucrative opportunities to industry players.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX